SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

21 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

14 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

06 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

05 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Provides Update on Strategic Priorities

08 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody

21 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

10 Nov 2022 09:00:03 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

08 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”

07 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference

02 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

30 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

21 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody

31 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

23 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

09 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

01 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference

25 May 2022 07:30:00 By Nasdaq GlobeNewswire